Table 3 |
||||
|
Meta-analysis of type-specific HPV DNA prevalence in invasive cervical cancer [15], updated with 63 newly published studies by Clifford (IARC) |
||||
|
N tested |
N pos |
% pos |
95% CI |
|
|
|
||||
|
hpv39 |
13370 |
172 |
1.29 |
1.10 – 1.48 |
|
hpv59 |
13471 |
172 |
1.28 |
1.09 – 1.47 |
|
hpv51 |
13057 |
151 |
1.16 |
0.97 – 1.34 |
|
hpv56 |
13247 |
103 |
0.78 |
0.63 – 0.93 |
|
hpv68 |
11982 |
73 |
0.61 |
0.47 – 0.75 |
|
hpv73 |
9939 |
48 |
0.48 |
0.35 – 0.62 |
|
hpv6 |
14912 |
68 |
0.45 |
0.35 – 0.56 |
|
hpv53 |
8140 |
34 |
0.42 |
0.28 – 0.56 |
|
hpv66 |
12118 |
47 |
0.39 |
0.28 – 0.50 |
|
hpv70 |
10503 |
35 |
0.33 |
0.22 – 0.44 |
|
hpv82 |
9265 |
25 |
0.27 |
0.16 – 0.38 |
|
hpv26 |
6111 |
8 |
0.13 |
0.04 – 0.22 |
|
|
||||
|
HPV types 30, 34, 67, 85 and 97 were not studied in the meta-analysis dataset. |
||||
|
Schiffman et al. Infectious Agents and Cancer 2009 4:8 doi:10.1186/1750-9378-4-8 |
||||